A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia
Joint Authors
Chen, Hongdou
Wang, Jin-na
Wang, Xu
Yu, Shu-le
Ding, Yue-hui
Wang, Meng-lei
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-04-30
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Objective.
To evaluate the difference of clinical efficacy of peramivir alone and peramivir combined with immunomodulators (either ribonucleic acid or thymopetidum) in the treatment of severe influenza A with primary viral pneumonia.
Methods.
A retrospective analysis was applied to 45 patients who were diagnosed with severe influenza A with primary viral pneumonia in our hospital from December 2017 to March 2018.
The cases were divided into three groups: the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group.
Results.
The duration of viral nucleic acid positivity in the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group was 6.13 ± 2.06, 6.53 ± 2.72, and 6.10 ± 1.37 days, respectively.
The remission time of the clinical symptoms of the peramivir group, the peramivir combined with ribonucleic acid group, and the peramivir combined with thymopetidum group was 8.06 ± 2.73, 7.94 ± 2.89, and 7.67 ± 1.58 days, respectively.
Comparisons between the peramivir group and the peramivir combined with ribonucleic acid group or the peramivir combined with thymopetidum group revealed no significant differences in the duration of virus nucleic acid positivity, remission time of clinical symptoms, time to fever alleviation, and time to cough alleviation.
Conclusions.
There is no observed benefit in the addition of ribonucleic acid or thymopetidum when peramivir sodium chloride injection is used in the treatment of severe influenza A with primary viral pneumonia.
This trial is registered with ChiCTR1800019417.
American Psychological Association (APA)
Wang, Jin-na& Wang, Xu& Yu, Shu-le& Ding, Yue-hui& Wang, Meng-lei& Chen, Hongdou. 2019. A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia. Canadian Respiratory Journal،Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1145716
Modern Language Association (MLA)
Wang, Jin-na…[et al.]. A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia. Canadian Respiratory Journal No. 2019 (2019), pp.1-5.
https://search.emarefa.net/detail/BIM-1145716
American Medical Association (AMA)
Wang, Jin-na& Wang, Xu& Yu, Shu-le& Ding, Yue-hui& Wang, Meng-lei& Chen, Hongdou. A Retrospective Analysis of Three Antiviral Regimens of Peramivir in the Treatment of Severe Influenza A with Primary Viral Pneumonia. Canadian Respiratory Journal. 2019. Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1145716
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1145716